Landos Biopharma (NASDAQ:LABP – Get Rating) issued its earnings results on Thursday. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02), MarketWatch Earnings reports.
Shares of LABP traded up $0.01 during trading hours on Friday, hitting $0.68. The stock had a trading volume of 195,826 shares, compared to its average volume of 120,036. Landos Biopharma has a 12-month low of $0.61 and a 12-month high of $16.17. The company’s fifty day simple moving average is $1.29 and its 200 day simple moving average is $4.19.
A number of research firms have recently commented on LABP. Zacks Investment Research raised shares of Landos Biopharma from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a research note on Wednesday, April 6th. Jefferies Financial Group lowered shares of Landos Biopharma from a “buy” rating to a “hold” rating in a report on Tuesday, April 12th. Finally, Raymond James cut their target price on shares of Landos Biopharma from $24.00 to $9.00 and set an “outperform” rating on the stock in a research note on Friday, March 25th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Landos Biopharma currently has an average rating of “Buy” and a consensus target price of $21.75.
Landos Biopharma Company Profile (Get Rating)
Landos Biopharma, Inc, a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA).
- Get a free copy of the StockNews.com research report on Landos Biopharma (LABP)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Landos Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Landos Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.